Dr. Reddy’s Laboratories names Marc Kikuchi new CEO for North America Generics business

Dr. Reddy’s Laboratories has appointed Marc Kikuchi as the Chief Executive Officer (CEO) of its North America Generics business. In his new role, Kikuchi will be responsible for overseeing the company’s North American generics operations, working out of the Princeton office in the United States.

With over 20 years of experience in the pharmaceutical industry, Marc Kikuchi brings a wealth of expertise to Dr. Reddy’s Laboratories. Known for his deep knowledge of generics, Kikuchi joins the company from Zydus Pharmaceuticals, where he served as CEO of the Americas since 2016. Prior to this, Kikuchi held senior leadership positions at prominent companies such as AmerisourceBergen, Medrad, PRTM, Johnson & Johnson, and Incyte Pharmaceuticals.

Marc Kikuchi expressed his enthusiasm about joining Dr. Reddy’s Laboratories, stating, “Dr. Reddy’s is a great company with a wide portfolio and remarkable heritage. I am excited to join Dr. Reddy’s and look forward to leveraging my past experiences to steer the Company’s new growth areas.” His appointment marks a significant step for Dr. Reddy’s Laboratories as it continues to strengthen its position in the generics market in North America.

Kikuchi’s educational background further reinforces his ability to lead in this space. He holds a Bachelor’s Degree in Molecular and Cell Biology with a Biochemistry emphasis from the University of California, Berkeley, and a Master of Business Administration (MBA) from Carnegie Mellon University, specialising in Strategy, Marketing, and Operations Management.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Related Posts
Read More

Lilly bags Taltz FDA approval for ankylosing spondylitis

Taltz FDA approval : The US Food and Drug Administration (FDA) has approved US pharma giant Eli Lilly and Company’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults having active ankylosing spondylitis (AS). Also known as radiographic axial spondyloarthritis (r-axSpA), ankylosing spondylitis is a type of spondyloarthritis that affects the pelvic joints and […]

The post Lilly bags Taltz FDA approval for ankylosing spondylitis appeared first on PharmaNewsDaily.com.